Letter to the Editor
Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy

https://doi.org/10.1016/j.cgh.2018.08.017Get rights and content

References (8)

  • R.P. Hirten

    Clin Gastroenterol Hepatol

    (2018)
  • S. Danese

    Ann Intern Med

    (2014)
  • B.E. Sands

    Inflamm Bowel Dis

    (2007)
  • R. Hirten

    Am J Gastroenterol

    (2015)
There are more references available in the full text version of this article.

Cited by (30)

  • Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies

    2023, Biomedicine and Pharmacotherapy
    Citation Excerpt :

    At week 14, all patients showed improvement in IBD symptoms without signs of arthritis, pain, or joint swelling, and no adverse events during treatment. Two case reports in 2019 [106,107] published 2 successful cases of UC being treated with VDZ plus TOFA. Both patients presented with UC with seronegative HLA B27 inflammatory spondyloarthritis; no adverse events were reported.

  • What place for targeted treatment associations?

    2022, Revue du Rhumatisme (Edition Francaise)
  • Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review

    2022, International Immunopharmacology
    Citation Excerpt :

    After primary screening, 226 studies were included for full-text analysis; 3 additional studies were identified from the reference lists of these studies. Eventually, 23 studies fulfilled the inclusion criteria [8–30]. A flow diagram reporting the literature search process is provided in Fig. 1.

  • Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

    2022, Clinical Gastroenterology and Hepatology
    Citation Excerpt :

    A total of 39 reports of 30 studies met inclusion criteria (Figure 1) and were included for extraction and analysis. Of these, 14 case reports, 6 case series, 9 observational cohort studies, and 1 randomized controlled trial were identified.8,9,12–53 All 30 studies were included for qualitative analysis; 10 studies with 10 or more patients were identified and included for quantitative analysis.

View all citing articles on Scopus

Conflicts of interest This author discloses the following: Laurent Peyrin-Biroulet has received honoraria from Pfizer and Takeda. The remaining authors disclose no conflicts.

View full text